$APH

UBS Adjusts Price Target on Amphenol to $105 From $99, Keeps Buy Rating

UBS raised its price target for Amphenol Corporation to $105 from $99 while maintaining a buy rating. The company recently announced executive changes effective January 1, 2027. Amphenol's stock has seen a 5.07% increase year-to-date and a 31.15% rise over the past year.

Original reporting
Published Oct 7, 2026, 1:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$APH
Bullish
high confidence
Mentioned
$APH
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$APHBullishMed
01

Why it matters

The higher target may attract buying interest, especially from investors tracking analyst upgrades.

02

Market read

Analyst target change is a modest catalyst for APH; limited broader market effect.

03

What to watch

Potential supply-chain constraints or macro headwinds could offset upside.

Relevance 6/10Novelty 6/10Timing: today

Background

UBS analyst updates valuation metrics and maintains a Buy recommendation for Amphenol.

Company-level read

Ticker impact

$APHBullishHigh confidence
Context

UBS raised its price target for Amphenol to $105 from $99 and kept a Buy rating.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise signals improved valuation expectations; market may bid the stock higher.

Market effects

May lift sentiment for the broader electronic components sector.

Limited to U.S. equities; no broader regional effect.

Low; impact confined to Amphenol and peers.

Counterpoint

Target raises can be premature; price may already reflect expectations.

Key entities

  • Amphenol Corporation

    U.S.-listed electronic components manufacturer (ticker APH).

  • UBS

    Investment bank providing the price target revision.

Related articles

$APHMed

Why Amphenol Stock Topped the Market on Tuesday

Amphenol (NYSE: APH) shares rose 1.6% on Tuesday, outperforming the S&P 500, after two analysts raised their price targets. Goldman Sachs increased its target to $116, while Baird raised it to $105. Both maintained buy ratings, citing Amphenol's role in supplying components for AI data centers.

$TTMIMed

Soaring Defense Spending Means Great News for These 2 Stocks

TTM Technologies (TTMI) and Amphenol (APH) have seen significant stock gains this year due to increased defense spending. TTM reported Q2 revenue of $1B (+37% YoY) and EPS of $0.77 (+92.5% YoY). Amphenol reported Q2 revenue of $8.8B (+55% YoY) and EPS of $1.37 (+59% YoY). Both companies benefit from defense electronics supply chain and AI infrastructure surges. They also have other revenue streams, with AI data center spending contributing significantly.

$APHMedAI 8/10

APH's AI Datacom Strength Grows: Can It Challenge TEL & MRVL?

Amphenol (APH) reported strong Q2 2026 results, with IT datacom sales up 89% YoY, driven by AI-related demand. AI revenue run rate reached $10.5-$11B. CommScope acquisition added $1.2B in sales. Competitors TEL and MRVL also reported growth in AI-related segments. APH stock up 16% YTD, trading at 25.32x forward P/E. Earnings estimates revised up to 72 cents per share.

$APHMed

APH Looks 5.7% Overvalued on GF Value™

Citi analyst Asiya Merchant initiated a 90-day catalyst watch on Amphenol Corp (APH), maintaining a Buy rating with a $105 target price. The firm cited benefits from AI and data center investments. APH is trading at $83.92, 5.7% above its GF Value™ of $79.43, indicating slight overvaluation. The company has a GF Score™ of 97/100, reflecting strong profitability and growth. Insider activity shows net selling over the past 12 months.

$APHMedAI 8/10

Is Amphenol Stock Outperforming the Dow?

Amphenol (APH) stock is down 18.3% from its 52-week high but up 46.5% over the past year, outperforming the Dow. Q2 2026 revenue rose 55% to $8.8B, beating estimates. Analysts rate it a 'Strong Buy' with a $200.50 price target. APH trades above its 200-day but below its 50-day moving average.